Philippines HIV Drugs Market Analysis Report 2022 to 2030

Philippines HIV Drugs Market Analysis

$ 3999

Philippines HIV Drugs Market is at around $69.74 Mn in 2023 and is projected to reach $92.39 Mn in 2030, exhibiting a CAGR of 4.1% during the forecast period. The market is growing as a result of government initiatives, the expansion of the healthcare infrastructure, and the rising prevalence of HIV/ AIDS. The market is dominated by key players like Unilab, Gilead Sciences, ViiV Healthcare, Boehringer Ingelheim International GmbH, Janssen Pharmaceuticals, Merck & Co., Bristol-Myers Squibb, AbbVie Inc., F. Hoffmann-La Roche Ltd., and Novartis.

ID: IN10PHPH011 CATEGORY: Pharmaceuticals GEOGRAPHY: Phillipines AUTHOR: Aneri Parekh

Buy Now

Philippines HIV Drugs Market Executive Summary

Philippines HIV Drugs Market is at around $69.74 Mn in 2023 and is projected to reach $92.39 Mn in 2030, exhibiting a CAGR of 4.1% during the forecast period.

The Philippines HIV Drugs Market is committed to manufacturing and supplying drugs for the country's use in the management and treatment of HIV/ AIDS. As the number of HIV cases rises, so does the need for efficient medications and treatment programs. This market is influenced by several variables, including international collaborations, healthcare infrastructure, and government regulations. The market includes a variety of antiretroviral medications, both imported and produced domestically.

The Philippines' market for HIV medications is steadily expanding as a result of rising public awareness of the illness and governmental efforts to combat it. To keep up with the rising demand for antiretroviral therapy, major players in the market are extending their reach through joint ventures and new product introductions. Although it is still difficult to find inexpensive treatment options, especially in rural areas, efforts are being made to address this problem through several healthcare initiatives.

HIV medication sales have risen rapidly, in 2023, the market was valued at $31.7 Bn. The primary driver of this growth is an increase in HIV diagnoses. The market is evolving as more generic substitutes become available and competition rises. To make therapy more accessible in developing countries, financial barriers to treatment must be addressed, HIV stigma reduced, and support services provided.

Unilab accounts for 15–25% of the HIV medication market in the Philippines. Antiretroviral drugs (ARVs) in both generic and branded formulations are available from Unilab. Retrovir (AZT), Combivir (AZT/3TC), Triomune (d4T/3TC/EFV), Kaletra (lopinavir/ritonavir), and Rescriptor (delavirdine) are a few of their well-known HIV products. Since Unilab owns its manufacturing facilities in the Philippines, it can create generic ARVs at a lower cost than brands that are imported. Patients in the country can afford HIV treatment more easily as a result of this.

Philippines HIV drugs market

Market Dynamics

Market Growth Drivers:

Rising HIV/ AIDS Prevalence: Antiretroviral therapy (ART) and other HIV drugs have been in demand in the Philippines as a result of an increase in HIV/ AIDS cases in recent years.

Government Initiatives: The Philippine government has taken a proactive stance in addressing the HIV/ AIDS crisis by introducing several initiatives, including expanded testing, public awareness campaigns, and treatment accessibility. The country's need for HIV medications is fuelled by these measures.

Expansion of Healthcare Infrastructure: The Philippines has been making investments in clinics and hospitals that are equipped to offer HIV testing, counseling, and treatment services. Patients nationwide have easier access to HIV medications as a result of this expansion.

Market Restraints:

Supply Chain Challenges: Problems with logistics of transportation, stockouts, and inefficiencies in the supply chain can make it difficult to ensure the availability of HIV medications, especially in rural areas.

Regulatory Obstacles: Regulatory obstacles can impede the release of novel treatments onto the market such as protracted approval procedures for new medications or treatment plans. This may restrict HIV patients' options for treatment and impede market expansion.

Lack of Awareness and Education: Despite initiatives to raise public awareness and educate people about HIV/ AIDS, there are still gaps in the general public's knowledge, especially in rural and marginalized communities. Lack of awareness about early testing and treatment may delay diagnosis and treatment, affecting HIV drug demand.

Healthcare Policies and Regulatory Landscape

The Philippine Food and Drug Administration (FDA) is the Implementing Body for the Abridged and Verification Review Pathways for New Drug Applications. Obtain the LTO. Next, apply to the FDA for a Certificate of Product Registration (CPR). This means that the product has successfully passed a thorough evaluation and has been officially registered with the Philippine FDA. The intricacy of fulfilling prerequisites and navigating the regulatory landscape may affect the speedy approval of drugs.

Competitive Landscape

Key Players:

Unilab
Gilead Sciences
ViiV Healthcare
Boehringer Ingelheim International GmbH
Janssen Pharmaceuticals
Merck & Co.
Bristol-Myers Squibb
AbbVie Inc.
F. Hoffmann-La Roche Ltd
Novartis

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

HIV Drugs Market Segmentation

By Drug Class

Integrase Inhibitors
Non- Nucleoside Reverse Transcriptase Inhibitors (NRTIs)
Combination HIV Medicines
Others

By Distribution Channel

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Others

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.